Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Current Assets (2016 - 2025)

Spero Therapeutics (SPRO) has disclosed Current Assets for 10 consecutive years, with $52.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Current Assets fell 60.25% year-over-year to $52.3 million, compared with a TTM value of $52.3 million through Sep 2025, down 60.25%, and an annual FY2024 reading of $107.3 million, down 18.24% over the prior year.
  • Current Assets was $52.3 million for Q3 2025 at Spero Therapeutics, down from $59.4 million in the prior quarter.
  • Across five years, Current Assets topped out at $157.9 million in Q4 2021 and bottomed at $52.0 million in Q2 2022.
  • Average Current Assets over 5 years is $104.6 million, with a median of $107.3 million recorded in 2024.
  • The sharpest move saw Current Assets surged 93.28% in 2023, then plummeted 60.25% in 2025.
  • Year by year, Current Assets stood at $157.9 million in 2021, then fell by 28.06% to $113.6 million in 2022, then rose by 15.53% to $131.2 million in 2023, then dropped by 18.24% to $107.3 million in 2024, then tumbled by 51.23% to $52.3 million in 2025.
  • Business Quant data shows Current Assets for SPRO at $52.3 million in Q3 2025, $59.4 million in Q2 2025, and $74.7 million in Q1 2025.